Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.70 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.70 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.70 |
| ▸ | GAA | P10253 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.48 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | RGS12 | O14924 | 1/20 | 0.47 |
| ▸ | APEX1 | P27695 | 1/20 | 0.47 |
| ▸ | THPO | P40225 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL756841 | 0.84 | PTGS1 (0.71) | PTGS1AKR1C3AKR1C2GAALMNA | |
| SCHEMBL4080225 | 0.84 | AKR1B1 (0.52) | PTGS1AKR1C3AKR1C2GAALMNA | |
| SCHEMBL3313524 | 0.83 | CA2 (0.61) | PTGS1AKR1C3AKR1C2GAALMNA | |
| SCHEMBL4194127 | 0.82 | LMNA (0.50) | PTGS1AKR1C3AKR1C2LMNATP53 | |
| SCHEMBL29871774 | 0.82 | LMNA (0.50) | PTGS1AKR1C3AKR1C2LMNATP53 | |
| 2-Naphthylacetic Acid SCHEMBL8987218 | 0.82 | PTGS1 (0.70) | PTGS1AKR1C3AKR1C2GAAALDH1A1 | |
| 6-Methoxy-2-Naphthylacetic Acid SCHEMBL253759 | 0.82 | AKR1C3 (1.00) | PTGS1AKR1C3AKR1C2GAALMNA | |
| 6-Methoxy-2-Naphthylacetic Acid SCHEMBL9504315 | 0.81 | AKR1C3 (0.97) | PTGS1AKR1C3AKR1C2GAALMNA | |
| 6-Methoxy-2-Naphthylacetic Acid SCHEMBL503709 | 0.81 | PTGS1 (0.97) | PTGS1AKR1C3AKR1C2GAALMNA | |
| 6-Methoxy-2-Naphthylacetic Acid SCHEMBL9504307 | 0.81 | AKR1C3 (0.97) | PTGS1AKR1C3AKR1C2GAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7193102-B2 | Process for the racemate resolution of 3-aminopentanenitrile | BAYER AKTIENGESELLSCHAFT (DE) | 2007-03-20 | — | — | US | claimed |
| US-20040087811-A1 | Process for the racemate resolution of 3-aminopentanenitrile | LANXESS DEUTSCHLAND GMBH (DE) | 2004-05-06 | — | — | US | claimed |
| WO-1997013519-A1 | ESTERS OF CYCLOOXYGENASE INHIBITORS AND TERPENE DERIVATIVES AS PHARMACEUTICAL PRODUCTS | RUSSINSKY LIMITED (IE) | 1997-04-17 | — | — | WO | claimed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| US-11191719-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2021-12-07 | — | — | US | disclosed |
| US-10463611-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2019-11-05 | — | — | US | disclosed |
| WO-2019055942-A1 | METHODS AND COMPOSITIONS TO INHIBIT TOLERANCE TO OPIOIDS | SEN-JAM Pharmaceutical LLC (US) | 2019-03-21 | — | — | WO | disclosed |
| US-20140154313-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2014-06-05 | — | — | US | disclosed |
| EP-2717860-A1 | CONTROLLED ABSORPTION WATER-SOLUBLE PHARMACEUTICALLY ACTIVE ORGANIC COMPOUND FORMULATION FOR ONCE-DAILY ADMINISTRATION | STI Pharma, LLC (US) | 2014-04-16 | — | — | EP | disclosed |
| WO-2012170676-A1 | CONTROLLED ABSORPTION WATER-SOLUBLE PHARMACEUTICALLY ACTIVE ORGANIC COMPOUND FORMULATION FOR ONCE-DAILY ADMINISTRATION | STI PHARMA, LLC (US) | 2012-12-13 | — | — | WO | disclosed |
| US-20120264605-A1 | Multi-Functional Ionic Liquid Compositions for Overcoming Polymorphism and Imparting Improved Properties for Active Pharmaceutical, Biological, Nutritional, and Energetic Ingredients | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2012-10-18 | — | — | US | disclosed |
| US-6242243-B1 | PURE CULTURE; FOR PRODUCTION OF HYDROLASE ENZYME USEFUL IN EFFICIENT RESOLUTION OF (+)-6-METHOXY-ALPHA-METHYL NAPHTHALENE ACETIC ACID ALKYL ESTERS; PRODUCTION OF NAPROXEN | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2001-06-05 | — | — | US | disclosed |
| WO-2000061549-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2000-10-19 | — | — | WO | disclosed |
| WO-2000013672-A1 | NEW SOLID DOSE FORM OF NANOPARTICULATE NAPROXEN | ELAN PHARMA INTERNATIONAL LTD (IE) | 2000-03-16 | — | — | WO | disclosed |
| US-5637320-A | Controlled absorption naproxen formulation for once-daily administration | ELAN CORPORATION, PLC (IE) | 1997-06-10 | — | — | US | disclosed |
| EP-0438249-B1 | Controlled absorption naproxen formulation for once-daily administration | ELAN CORP PLC (IE) | 1995-08-09 | — | — | EP | disclosed |
| EP-0644940-A1 | PROCESS FOR ENZYMATIC PREPARATION OF -i(S)-6-METHOXY-A-METHYL-2-MAPHTHALENEACETIC ACID | SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED (BM) | 1995-03-29 | — | — | EP | disclosed |
| EP-0438249-A1 | Controlled absorption naproxen formulation for once-daily administration | ELAN CORPORATION PLC (IE) | 1991-07-24 | — | — | EP | disclosed |
| US-4672077-A | Novel soluble salt having analgesic and anti-inflammatory activity, a process for the preparation thereof and pharmaceutical forms containing them | ISTITUTO BIOCHIMICO PAVESE SPA (IT) | 1987-06-09 | — | — | US | disclosed |
| EP-0007116-B1 | METHOD FOR RESOLVING RACEMIC 6-METHOXY-ALPHA-METHYL-2-NAPHTHALENE ACETIC ACID INTO ITS ENANTIOMERS AND RESOLVING MEDIUM | SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED (BM) | 1983-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264605-A1 | Multi-Functional Ionic Liquid Compositions for Overcoming Polymorphism and Imparting Improved Properties for Active Pharmaceutical, Biological, Nutritional, and Energetic Ingredients | SLC5A6, PNLIP, IPMK | PTGS1 1863/4885AKR1C3 3168/4885AKR1C2 3274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.